AWIC 2016 – Innovation Program

Shudong Wang

April 2016
University Facts and Statistics

南澳大学介绍

- The University of South Australia is a globally-focused, locally-engaged institution established on the dual principles of equity and excellence. 南澳大学是基于平等和卓越双重原则而设立拥有国际视野的澳洲大学。

- It is the largest university in South Australia, delivering more than 400 degree programs to over 32,000 students. 是南澳大利亚州最大的大学,拥有超过400门学位课程和32,000名学生。

- It ranks in the top 3% of universities worldwide. 位列世界前3%的顶级高等学府。

- Ranked at 25 in the world for Universities aged under 50, 2015/16 QS Top 50 under 50 rankings. 世界校龄小于50年的大学排名第25位。
In 2015 the Excellence in Research Australia (ERA) results were released.

2015年“澳大利亚杰出研究计划”评比：

- 97% of UniSA’s Evaluated Research is rated at world class or above. 南澳大学97%研究被列为世界一流水平

- 18 Research Fields received a Top 5 rating for research excellence that is well above world standard. 18个研究领域被列为世界前5名顶尖水平
The University of South Australia has an active China engagement strategy including: 南澳大学与中国的合作包括：

• The China-Australia Centre for Health Science Research with Shandong University. 建立中澳健康科学研究中心

• Undertakes research in pharmaceutical sciences, medicine, and public and population health. 开展药学，医学，公共卫生和健康学研究

• Matched funding (A$1m) of 40 joint projects now delivering joint publications, grants and patents. 支持40个合作研究项目
Health Science Capabilities

Pharmacy and Medical Sciences
Rehab, Health and Sports Sciences
Nursery and Midwifery

Drug discovery and development
Pharmaceutical Sciences
Cell biology
Vaccines

Material sciences
Wound care applications
Biosensors

Cancers: Leukaemia and solid tumour

Surface technologies
Nanotechnologies
Formulation technologies
Named after eminent Australian pharmacist Professor Lloyd Sansom, the Sansom Institute encompasses a unique research that extends across the entire health spectrum. 是以澳大利亚最著名药学家Sansom教授命名的医药健康研究院。

Aims to prevent illness and creating effective therapies. 旨在预防疾病，创造发明有效的治疗途径。

250 members and 200 PhD students across a diverse range of cutting edge projects. 有研究人员超过250人，博士学生超过200人

Annual research income more than $20m 年研究经费超过$200万澳元

Currently collaborating with <120 institutions in 22 countries 现与22个国家120个研究院合作
Our mission is to take the path from understanding a disease to bring a safe and effective new drug to patients. 我们的使命是为病人创造有效和安全的新药

We work to:

• validate diseases targets 确认疾病靶标
• discover the right molecule to interact with the target chosen 发现候选药使其能与该靶标作用
• test the new compound in the laboratory and clinic for safety and efficacy 进行实验及临床药物药效和安全评估
• gain approval and get the new drug into the hands of doctors and patients 申报注册并将新药送到医生病人手中
Our Capabilities at CDDD
本中心的研究范围

- Computational and structure-based drug design and screening
  计算机和结构辅助药物的设计和筛选
- Advanced synthetic and medicinal chemistry
  最先进的药物化学及合成
- Target-driven biochemical and cell-based assays
  靶标驱动的生物化学和细胞测定
- ADME/Tox and pharmacology
  临床前ADME/安全性/药代动力学研究
- Pre-clinical evaluation and drug development
  临床前药物开发申报
Computer-aided Drug Design 计算机辅助药物设计和评估：
• Molecular dynamics simulations 分子动力学模拟
• Structure based drug design & screening 以结构为基础的药物设计和筛选
• Computational biology and pharmacology 计算机生物学和药学
Structure- and pharmacology-guided Medicinal Chemistry
结构和药理辅助的药物化学:
• Synthesise drug molecules with specific biological and therapeutical activity 合成选择性好，成药性强的创新型候选药物
Target-driven Biology, Pharmacology and Toxicology

靶标驱动的生物药理学和毒理学：

Investigate potency, stability, safety and mechanism of drug actions

研究候选药物的生物活性, 稳定性, 安全性和作用机理.

Untreated cervical cancer cells

Our drug candidate MKI-18 kills the cancer cells
有关创新药项目的合作，开发，转让和研发技术咨询等，请联系:
Prof. Shudong Wang
shudong.wang@unisa.edu.au